TN trans care ban: AG said defending case to SCOTUS, expected to rule soon, was God's will
"I'm in the middle of things that are so much bigger than I have any business being in the middle of. But I'm there for a reason," Tennessee Attorney General Jonathan Skrmetti said during a June 10 panel discussion at the Kay Bailey Hutchison Convention Center in Dallas. 'So, I just try to remember it's not about me and that God puts his people where he needs them, where he wants them."
Skrmetti's office is defending Tennessee's ban on gender transition treatments for transgender minors, which a Nashville family with a transgender teenager is challenging. The Supreme Court may decide on the case as early as June 12, and a majority of justices have signaled a friendly disposition toward upholding Tennessee's law that took effect in June 2023.
The June 10 event was organized by the Nashville-based SBC's public policy arm, the Ethics & Religious Liberty Commission. Skrmetti and another panelist, Alliance Defending Freedom senior vice president Ryan Bangert, said the case is about science and the degree to which courts can decide public policy. But Skrmetti and Bangert, whose law firm is helping represent Tennessee in U.S. v. Skrmetti, acknowledged faith is another key component of this story and will potentially be a resounding victory for conservative Christians.
More: Meet the Tennessee family behind the US Supreme Court's major transgender health care case
'I would be ready to have good conversations with your congregants, good conversations with your fellow church members about what this case means not just from a legal perspective. But from a broader cultural perspective,' Bangert said at the June 10 panel. 'I would be ready to have that conversation: 'God willing, the law has been upheld. What do we do know?''
Alliance Defending Freedom has been a decisive force in several recent U.S. Supreme Court cases that have reversed precedent in favor of conservative Christian ideals. Examples include Dobbs v. Jackson Women's Health Organization that overturned Roe v. Wade, Kennedy v. Bremerton dealing with public prayer on a high school sports field, and 303 Creative v. Elenis about a Christian web designer's refusal to work with same-sex couples.
The Southern Baptist Convention is the nation's largest Protestant denomination. The Ethics & Religious Liberty Commission stated its opposition to transition treatment for transgender people in resolutions at past SBC annual meetings and has been a vocal proponent of bans in Tennessee and other states. Bangert said at the June 10 panel there are 26 states with bans like Tennessee's and the decision in U.S. v. Skrmetti could affect those other laws.
The ERLC filed an amicus brief in U.S. v. Skrmetti, for which the SBC-affiliated agency hired a Southern Baptist lawyer to carefully and forcefully assert the Southern Baptists' position on the issue.
Skrmetti praised the ERLC's amicus brief during the June 10 panel, saying it provided a theological rationale for Tennessee's law. Skrmetti's office cannot make that theological argument in its defense before the Supreme Court because an establishment clause requires the state to approach the case from a religiously neutral perspective.
Skrmetti, who attends a Church of Christ congregation in Nashville, said at the June 10 panel in his capacity at Tennessee's attorney general that his religion is not a factor in how he approaches the case. But personally, he told the crowd of Southern Baptists in Dallas that the outcome will be meaningful as a person of faith.
'Pray for my team that all of us that if we win, win gracefully in a way that reinforces both shining God's light into the world,' Skrmetti said.
Liam Adams covers religion for The Tennessean, part of the USA TODAY Network. Reach him at ladams@tennessean.com or on social media @liamsadams.
This article originally appeared on Nashville Tennessean: Skrmetti cites God's will to his role in SCOTUS trans care case at SBC
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Skift
27 minutes ago
- Skift
Congress Travel – All Expenses Paid: Top Destinations and Sponsors
They're among the platinum perks members of Congress and their staffers enjoy: expenses-paid trips, often to luxurious destinations in the United States and abroad. And special interest groups are footing the travel bills. Federal lawmakers and their staffers have so far taken more than 1,700 of these trips this year, according to a Skift analysis of congressional records through July. The journeys are generally permitted by U.S. House and Senate rules as long as the itineraries are pre-approved by ethics officials, properly disclosed, and not bankrolled by a registered lobbyist or foreign agent. Most are sponsored by nonprofit or business organizations and designed to educate the official about a particular issue or industry, from global finance to national security to AI. But some government watchdogs say these trips are often little more than junkets, particularly since many of them take place in desirable locations and involve hig
UPI
28 minutes ago
- UPI
Guyana faces elections amid oil boom, Maduro's threats
Venezuelan President Nicolas Maduro has intensified his rhetoric over a long-standing territorial claim to the Essequibo, a region that makes up more than 60% of Guyana's territory. File Photo by Miguel Gutierrez/EPA Aug. 14 (UPI) -- With less than three weeks before Guyana's general elections Sept. 1, Venezuelan President Nicolás Maduro has intensified his rhetoric over a long-standing territorial claim to the Essequibo, a region that makes up more than 60% of Guyana's territory and that Caracas claims as its own. The region bordered by Venezuela on the west, Brazil on the southwest and the Atlantic Ocean on the north: It contains dense rainforests, highlands, savannas and low coastal plains. In his weekly address Tuesday, Maduro said Venezuela "will recover the Essequibo sooner rather than later," a statement that heightens diplomatic tensions at a sensitive moment for the English-speaking nation, which is preparing to elect a new parliament and president amid an unprecedented oil boom and growing regional polarization. "No matter what ExxonMobil, imperialism or the International Court of Justice do, the Essequibo is and will be Venezuela's," the Venezuelan president said, firmly rejecting any ruling from the Hague-based court. While such remarks are not new in Venezuela's official rhetoric, they come as Guyana gains international prominence thanks to the rapid development of its oil industry in the offshore area adjacent to the Essequibo. Major companies such as ExxonMobil, Hess and CNOOC operate there under concessions challenged by Caracas. Guyana President Irfaan Ali, seeking re-election with the People's Progressive Party/Civic, has avoided direct confrontations with Venezuela, but has firmly defended Guyanese territory before the international community. The country has brought the dispute before the international court since 2018 and has reiterated its willingness to accept the court's ruling as binding. The case is moving forward in The Hague, with hearings held in April. Venezuela continues to reject the court's jurisdiction, while Guyana's government has received diplomatic backing from Caribbean nations, the Commonwealth, the United States and the Organization of American States. "The sovereignty of the Essequibo is not at stake. Guyana is committed to the peaceful resolution of the conflict in accordance with international law," the Ministry of Foreign Affairs said recently. Analysts say the Venezuelan government may be using the territorial claim for electoral purposes as it faces international sanctions and the recent U.S. announcement of a $50 million reward for information leading to the arrest and/or conviction of Maduro. U.S. Attorney General Pam Bondi accused him of working with criminal organizations, calling him one of the world's most dangerous drug traffickers and a threat to U.S. national security. By contrast, for Guyana, defending the Essequibo is a matter of national unity. In 2023, after a consultative referendum promoted by Maduro -- in which Venezuelans backed creating a state called "Guayana Esequiba" -- the Guyanese government strengthened its diplomatic strategy and stepped up its appeals at the United Nations. Guyana's political climate remains tense but stable, with seven parties registering candidates for the elections. The vote will be monitored by missions from the European Union, the Caribbean Community, or Caricom, and the Carter Center, which already has personnel deployed across the country. The Essequibo has not dominated the campaign debates, which are focused instead on economic development, equitable access to oil revenues and the fight against corruption. Guyana is undergoing an unprecedented economic transformation, driven by a surge in oil production. In 2024, the economy grew 43.6%, with the oil sector expanding 57.7% and the non-oil sector 13.1%. The International Monetary Fund projects average annual growth of 14% over the next five years, supported by stronger infrastructure and higher productivity, with non-oil GDP expected to grow about 6.75%. On the oil front, Guyana has begun production from its fourth floating production, storage and offloading unit, boosting capacity to more than 900,000 barrels per day -- already surpassing Venezuela's current output -- with a goal of reaching between 1.3 million barrels by 2027 and up to 1.7 million by 2030.
Yahoo
an hour ago
- Yahoo
VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer
Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing market SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the 'Company' or 'VivoSim Labs'), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ('3D') human tissue models of liver and intestine, announced today that it has appointed Tony Lialin as its Chief Commercial Officer. Mr. Lialin brings more than two decades of experience turning breakthrough life science platforms into scalable, predictable revenue. He has built commercial teams from the ground up, forged strategic pharma partnerships, and helped scale multiple businesses that were later acquired by leading industry players. At VivoSim Labs, he will lead go-to-market strategy, partnerships, and the expansion of the Company's San Diego-based services that combine organ-specific 3D models with AI-driven analytics to deliver decision-ready insights earlier in development. Market Opportunity: According to an internal analysis conducted by VivoSim Labs in July 2025, the global combined liver and gastrointestinal in-vitro models and toxicology services market generated $641M in revenue in 2024. Services represented 53.1% of revenue vs. models at 46.9% of revenue. The United States accounted for $325M (50.8%) of the global market for liver toxicology models and services. Adoption of 3D human-relevant systems is rising, with the global in vitro liver model market growing at 5.9% CAGR from 2020 to 2024. Category Tailwinds: Biopharma sponsors are accelerating the use of non-animal new approach methodologies (NAMs). Regulatory momentum, including the FDA Modernization Act 2.0 (2022), supports validated alternatives and is catalyzing broader adoption of human-relevant in vitro models for ADME and toxicology. How AI Helps: VivoSim Labs applies AI to quantify multi-parametric toxicity signatures across liver and intestinal organoid assays. By improving signal-to-noise in dose-response analyses, the platform helps project teams prioritize candidates and plan studies with greater confidence. 'VivoSim Labs sits at the intersection of biology and AI. Our NAMkind™ models are designed to answer make-or-break questions earlier,' said Tony Lialin, Chief Commercial Officer, VivoSim Labs. 'We will scale a high-touch, consultative service from our San Diego lab so pharma and biopharma teams get decision-ready toxicology insights that aim to streamline pre-IND decision-making and reduce late-stage surprises.' 'Tony has a rare track record of turning disruptive science into durable commercial engines,' said Keith Murphy, Executive Chairman, VivoSim Labs. 'As sponsors move rapidly to 3D, human-relevant models, they want a partner—not just a plate or a protocol—to guide critical decisions. Tony knows how to build the solutions that our customers need.' About VivoSim Labs VivoSim Labs, Inc. ("VivoSim" and the 'Company'), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ('3D') human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies ("NAM") models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration ('FDA") announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit Forward-Looking Statements Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding expansion of the Company's San Diego-based services; the potential for the Company's organ-specific 3D models and AI-driven analytics to deliver decision-ready insights earlier in development; the market opportunity and market size of gastrointestinal in-vitro models and toxicology services; and the ability of the Company's services to improve signal-to-noise in dose-response calls or help project teams prioritize candidates and studies with greater confidence. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company's filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 5, 2025, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events. ContactInvestor Relationsinfo@ Labs, in to access your portfolio
